Literature DB >> 16424659

Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine.

Lisa J Anderson1, Mark A Westwood, Emma Prescott, J Malcolm Walker, Dudley J Pennell, Beatrix Wonke.   

Abstract

It is believed that myocardial iron deposition and the resultant cardiomyopathy only occur in the presence of severe liver iron overload. Using cardiovascular magnetic resonance, it is now possible to assess myocardial and liver iron levels as well as cardiac function in the same scan, allowing this supposition to be examined. We describe a patient with progressive myocardial iron deposition and the development of early iron overload cardiomyopathy despite excellent compliance to standard subcutaneous desferrioxamine, minimal liver iron and well-controlled serum ferritin levels. These indirect markers remained far below the thresholds conventionally believed to be associated with increased cardiac risk. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424659     DOI: 10.1159/000089475

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  25 in total

1.  ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  W Gregory Hundley; David A Bluemke; J Paul Finn; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Vincent B Ho; Michael Jerosch-Herold; Christopher M Kramer; Warren J Manning; Manesh Patel; Gerald M Pohost; Arthur E Stillman; Richard D White; Pamela K Woodard
Journal:  Circulation       Date:  2010-05-17       Impact factor: 29.690

Review 2.  ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  W Gregory Hundley; David A Bluemke; J Paul Finn; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Vincent B Ho; Michael Jerosch-Herold; Christopher M Kramer; Warren J Manning; Manesh Patel; Gerald M Pohost; Arthur E Stillman; Richard D White; Pamela K Woodard
Journal:  J Am Coll Cardiol       Date:  2010-06-08       Impact factor: 24.094

Review 3.  Magnetic resonance imaging measurement of iron overload.

Authors:  John C Wood
Journal:  Curr Opin Hematol       Date:  2007-05       Impact factor: 3.284

Review 4.  Liver iron content determination by magnetic resonance imaging.

Authors:  Konstantinos Tziomalos; Vassilios Perifanis
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

Review 5.  Use of magnetic resonance imaging to monitor iron overload.

Authors:  John C Wood
Journal:  Hematol Oncol Clin North Am       Date:  2014-08       Impact factor: 3.722

Review 6.  Cardiovascular magnetic resonance T2* for tissue iron assessment in the heart.

Authors:  Taigang He
Journal:  Quant Imaging Med Surg       Date:  2014-10

7.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

Review 8.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

Review 9.  Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases.

Authors:  John C Wood; Nilesh Ghugre
Journal:  Hemoglobin       Date:  2008       Impact factor: 0.849

10.  Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.

Authors:  Anil Pathare; Ali Taher; Shahina Daar
Journal:  Ann Hematol       Date:  2009-10-02       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.